Spots Global Cancer Trial Database for Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer
Official Title: Clinical Study of Personalized Tumor Vaccines mRNA-0217/S001 and Pabolizumab in Patients With Advanced Pancreatic Cancer
Study ID: NCT05916261
Conditions
Interventions
Study Description
Brief Summary: The main objective of this study was to observe and evaluate the safety and tolerability of mRNA-0217/S001 vaccine encoding personalized tumor neoantigens alone/in combination with Pembrolizumab injection for the treatment of Advanced Pancreatic Cancer. The secondary objective was to observe the preliminary efficacy of mRNA-0217/S001 personalized tumor vaccine in the treatment of advanced solid tumors with neoantigen-specific CD4+ and CD8+ T lymphocyte responses, objective tumor response rate (ORR) and disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) caused by mRNA-0217/S001 personalized tumor vaccine.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ruijin-Hainan Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Qionghai, Hainan, China
Contact Details
Name: Baiyong Shen, M.D.&Ph.D
Affiliation: Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
